News & Insights

News & Insights

Home > News & Insights
2026.10.23
LongRiver Portfolio Company PepStar Signs Agreement with Gilead for $1.275 Billion Upfront
On October 22, Gilead Sciences announced a definitive agreement to acquire PepStar Therapeutics’ oral IL-23R inhibitor program, including lead candidate HCXT-2001, for $1.275 billion in upfront cash consideration.
More
2026.09.29
LongRiver Portfolio Company SciBrunch Announces Exclusive Global License Agreement with MSD for SPR2015
Agreement includes a $400 million upfront payment and a total potential value of up to $2.13 billion.
More
2026.09.09
LongRiver Investments Holds 2026 Annual Conference in Shanghai
LongRiver Investments held its 2026 Annual Conference in Shanghai on September 2, 2026.
More
2026.03.24
LongRiver Portfolio company Ouro Medicines Enters into Definitive Agreement to be Acquired by Gilead Sciences
LongRiver portfolio company, Ouro Medicines, has entered into a definitive agreement to be acquired by Gilead Sciences.
More
2025.09.15
LongRiver Investments Successfully Hosted Its 2025 Annual Conference
On September 8, LongRiver Investments hosted its 2025 Annual Conference in Liangxi, Wuxi, under the theme “Sail Beyond, Quest Profound.”
More
12